Bronchopulmonary Dysplasia

1. Disease Information

Overview. BPD is a chronic lung disease of prematurity. Injury to the immature lung, from oxygen, ventilation and inflammation, arrests alveolar and microvascular development ("alveolar simplification"). Thébaud 2019 frames it as an injury process occurring while the lung is still developing, then repairing and remodelling over months to years.

Identifiers - MONDO:0019091 (given in the template; verify). - ICD-10-CM P27.1 (BPD originating in the perinatal period). ICD-11 CA20.0, from memory, verify. - MeSH D001997. - OMIM: none, because the disease is multifactorial. Orphanet: not a rare Mendelian entry.

Synonyms. Chronic lung disease of prematurity (CLD); neonatal chronic lung disease; "old" (Northway) vs "new" BPD.

Definition history - Northway 1967 described classic BPD in ventilated, larger preterm infants. Its histology showed fibrosis, squamous metaplasia and airway injury. - NICHD 2001 (Jobe & Bancalari) defined BPD by oxygen need at 28 days, graded at 36 weeks postmenstrual age (PMA) as mild, moderate or severe. - NICHD 2018 (Higgins) and Jensen 2019 (an evidence-based definition) grade severity by respiratory support at 36 weeks PMA. Jensen 2019 is Grade 1 = nasal cannula ≤2 L/min, Grade 2 = >2 L/min or NIPPV/CPAP, Grade 3 = invasive ventilation, with a "2A/3A" early-death category. Grade boundaries are from memory.

Data source. Disease-level aggregate, not EHR-derived.

2. Etiology

Causal factors. BPD is multifactorial, with prematurity as the necessary background. The main drivers are: - Hyperoxia and oxidative stress. - Mechanical ventilation (volutrauma and barotrauma). - Antenatal and postnatal infection or inflammation (chorioamnionitis, sepsis). - Pulmonary insufficiency of prematurity and a patent ductus arteriosus (PDA).

Risk factors - Lower gestational age and birth weight are the dominant risk factors. - Fetal growth restriction, male sex, chorioamnionitis, postnatal sepsis and prolonged ventilation also raise risk. - Maternal smoking, preeclampsia and PDA are further associated factors. - Genetic risk: twin studies report high heritability (on the order of 50–80%). I recall Bhandari 2006 and Lavoie 2008, with no confident PMIDs. - GWAS have found no robust locus. - Candidate genes, such as SPINK1 and surfactant protein genes (SFTPB), are inconsistent. - Genetic note for curation: use relationship_type: SUSCEPTIBILITY or MODIFIER. Do not use CAUSATIVE.

Protective factors - Antenatal corticosteroids and female sex. - Caffeine (the CAP trial showed lower BPD). - Breast milk. - Gentle ventilation and noninvasive support.

Gene–environment interaction. Inferred rather than demonstrated: genetic susceptibility to oxidative injury, for example, interacts with hyperoxia exposure.

3. Phenotypes (HPO leads, verify)

Frequencies are not reliably sourced here. Reported BPD incidence depends on definition (see section 9).

Course. Onset is neonatal. Severity ranges from mild to severe. Symptoms improve with lung growth but can persist. Quality-of-life data are not retrieved in this report.

4. Genetic / Molecular Information

• Causal genes: none established; BPD is non-Mendelian.
• Susceptibility and modifier genes: inconsistent candidate-gene results. Surfactant genes (SFTPB, ABCA3 and SFTPC) cause interstitial lung disease in neonates and are differentials, not BPD causes.
• Epigenetics: altered DNA methylation in cord blood and tracheal aspirates has been reported. This is not verified here.
• Chromosomal abnormalities: none characteristic. FOXF1 and TBX4 variants mimic BPD with pulmonary hypertension.

5. Environmental Information

• Environmental: supplemental oxygen (hyperoxia), mechanical ventilation, and postnatal steroids as a treatment confounder.
• Lifestyle: maternal smoking in pregnancy.
• Infectious agents: Ureaplasma species are associated with BPD. Causality is not demonstrated, and trials of azithromycin for Ureaplasma have been inconclusive.
• ECTO leads (verify): hyperoxia exposure and tobacco-smoke exposure.

6. Mechanism / Pathophysiology

Causal chain (steps marked "inferred" are not directly demonstrated in humans)

1. Preterm birth interrupts the canalicular/saccular stages of lung development. The lung has surfactant deficiency and few alveoli.
2. This leads to respiratory failure requiring ventilation and oxygen.
3. Hyperoxia and ventilation produce oxidative stress and mechanical stretch injury of the epithelium.
4. Prenatal or postnatal infection and inflammation add cytokine signaling (IL-1β, IL-6, IL-8, TNF-α) and neutrophil/macrophage recruitment.
5. This leads to epithelial injury, apoptosis and disrupted growth-factor signaling, including VEGF, in the immature lung. The loss of VEGF signaling in the alveolar capillary network is inferred largely from animal models.
6. This leads to arrested alveolarization and impaired microvascular development, giving alveolar simplification, fewer and larger alveoli, and a dysmorphic capillary bed.
7. This leads to reduced gas-exchange surface area, causing chronic hypoxemia and oxygen dependence.
8. Branch A: vascular remodelling and raised pulmonary vascular resistance lead to pulmonary hypertension and right heart strain.
9. Branch B: airway smooth muscle hypertrophy and remodelling lead to airway hyperreactivity and wheeze.
10. Long-term, incomplete lung growth leads to persistent airflow obstruction in adulthood (COPD-like trajectory, inferred).

GO / CL leads (verify) - Processes: response to hyperoxia (GO:0055093), inflammatory response (GO:0006954), alveolar development (GO:0048286), angiogenesis (GO:0001525), apoptotic process (GO:0006915), response to oxidative stress (GO:0006979), extracellular matrix organization (GO:0030198). - Cells: type II pneumocyte (CL:0002063), pulmonary alveolar epithelial cell, lung endothelial cell, alveolar macrophage (CL:0000583), fibroblast (CL:0000057), airway smooth muscle cell (CL:0002062).

Molecular profiling. Not retrieved here. Check GEO for neonatal lung and tracheal-aspirate transcriptomics before adding a datasets: block. Per CLAUDE.md, run just verify-datasets and manually check disease relevance. Single-cell lung atlases of hyperoxia-injured neonatal mouse lung exist, but were not verified.

7. Anatomical Structures Affected

• Primary: lung (UBERON:0002048), specifically the alveolus (UBERON:0002299) and the terminal airways and pulmonary vasculature.
• Secondary: heart (right ventricle, via pulmonary hypertension); brain (neurodevelopmental effects in severe BPD); growth and nutrition.
• Localization: bilateral and diffuse, with heterogeneous regional involvement on imaging.
• Subcellular: mitochondria (oxidative stress) and the endoplasmic reticulum (surfactant protein handling); not verified.

8. Temporal Development

• Onset: neonatal. The diagnosis is made at 36 weeks PMA (or at 28 days in the 2001 definition).
• Stages: the acute neonatal injury phase, then a chronic phase with repair and remodelling over months to years (Thébaud 2019). Do not curate phases as separate entries; list them under progression:.
• Course: most infants wean off oxygen in infancy, but a subset have severe disease with tracheostomy, home ventilation or pulmonary hypertension.
• Critical periods: the first postnatal days (ventilation, oxygen and early caffeine) and the late-gestation window (antenatal steroids).

9. Inheritance and Population

• Inheritance: multifactorial; no Mendelian pattern. Twin heritability is high.
• Incidence and prevalence: about 40% of infants born before 28 weeks, and 10,000–15,000 new US cases annually (from memory). Because the figure depends on the definition used, record the definition with each rate: measure_type, rate_denominator: LIVE_BIRTHS, and the cohort in population. Verify against the NICHD Neonatal Research Network (Stoll et al.).
• Demographics:
• Affected infants are mostly those born extremely preterm; survival improvements have increased the number of survivors with BPD.
• Boys are at higher risk.
• Geographic variation reflects differences in NICU practice.

10. Diagnostics

• Clinical criteria: NICHD 2001, NICHD 2018 and Jensen 2019 (see section 1), all based on respiratory support at 36 weeks PMA.
• Imaging: chest X-ray (hazy lungs, cystic or fibrotic changes in classic BPD), lung ultrasound, and CT or MRI in selected cases.
• Echocardiography: screen for pulmonary hypertension.
• Functional tests: infant pulmonary function testing; later spirometry (reduced FEV1).
• Biomarkers: research only, with no validated clinical biomarker. Candidates include cytokines and endostatin; not verified.
• Genetic testing: not routine. Consider surfactant-gene and FOXF1/TBX4 testing in atypical or term-infant presentations.
• Differential diagnosis: surfactant protein deficiency, ILD of infancy, pulmonary vascular disease, congenital heart disease and aspiration.
• Screening: none for the disease itself. Risk stratification tools exist (the NICHD BPD outcome estimator); not verified.

11. Outcome / Prognosis

• Mortality is higher in severe BPD (see Jensen 2019 for outcome by grade).
• Survivors have more respiratory hospitalizations in early childhood, with persistent obstruction and reduced exercise capacity into adulthood.
• Neurodevelopmental impairment is more frequent.
• Complications include pulmonary hypertension, cor pulmonale, growth failure and airway malacia.
• Prognostic factors: gestational age, severity grade, pulmonary hypertension and ventilator dependence.
• No pooled survival numbers were verified for this report.

12. Treatment

NCIT treatment-term leads (verify): NCIT:C15986 (Pharmacotherapy), NCIT:C15747 (Supportive Care), NCIT:C15447 (Dietary Intervention).

• Pharmacotherapy (prevention and treatment)
• Caffeine citrate (CHEBI:27732, verify). The CAP trial (Schmidt 2006, PMID 16943402 unverified) showed a lower BPD rate. Search results note that earlier initiation seems more effective; a 2025 meta-analysis reported lower BPD but higher mortality with early caffeine.
• Antenatal corticosteroids: strong evidence for preventing BPD.
• Low-dose hydrocortisone in the first days prevents BPD but was associated with more late-onset sepsis in infants born at 24–25 weeks (search-result summary of the management review).
• Postnatal dexamethasone has benefits and neurodevelopmental risks; the timing and dose tradeoffs were not verified.
• Intramuscular vitamin A reduces BPD but is painful, expensive and not widely used.
• Diuretics and inhaled bronchodilators help symptoms; the evidence for long-term benefit is weak.
• Pulmonary hypertension: sildenafil, for which the evidence is limited.
• Respiratory support: surfactant, less-invasive surfactant administration, noninvasive ventilation, volume-targeted ventilation, and oxygen saturation targeting.
• Cell and gene therapy: mesenchymal stromal cell trials are in phase I/II. I do not have NCT numbers; search ClinicalTrials.gov and fetch each record before citing it.
• Supportive: nutrition, growth support, infection avoidance and pulmonary rehabilitation.
• Surgical: tracheostomy for prolonged ventilator dependence.

13. Prevention

• Primary: prevention of preterm birth, antenatal corticosteroids, and avoidance of maternal smoking.
• Respiratory strategy: gentle ventilation, noninvasive support, and early caffeine.
• Tertiary: avoid respiratory infection (RSV prophylaxis, vaccination) and optimize growth.
• Counseling: parental counseling about outcomes; not verified further.

14. Other Species / Natural Disease

Naturally occurring BPD is not established in other species. Preterm lambs and baboons are used experimentally (see section 15). NCBITaxon leads (verify): Ovis aries (NCBITaxon:9940), Papio (NCBITaxon:9554), Mus musculus (NCBITaxon:10090).

15. Model Organisms

Use the animal_models: section (not experimental_models), and link each model to a pathophysiology node via modeled_mechanisms with fidelity and limitations.

• Hyperoxia-exposed neonatal rodents (mouse and rat). Postnatal hyperoxia gives alveolar simplification and impaired angiogenesis. Fidelity is limited because rodent lungs are saccular rather than alveolar at birth, so the developmental stage differs from that of a preterm human.
• Preterm baboon (the 125-day, ventilated model), which reproduces "new BPD" most closely. Practical limits are cost and availability.
• Preterm lamb. Similar fidelity strengths, with a larger-animal practical burden.
• In vitro: lung organoids and iPSC-derived lung models, plus hyperoxia-exposed cell culture. Evidence source is IN_VITRO.
• Genetic models: VEGF-pathway and related knockouts show the role of vascular signaling. The specific mouse lines and MGI identifiers were not verified.

Curation Cautions (CLAUDE.md-specific)

1. Granularity. Treat BPD as a single disease entry, with severity grades as has_subtypes or stages only if the sources support it. The "old/new BPD" split can be a note.
2. Genetic section. No causative genes; use susceptibility or modifier typing, and leave gene_disease_validity absent because no external classification exists.
3. Prevalence. Use structured Prevalence slots with measure_type and rate_denominator, not free text.
4. Evidence. Quote only from cached references after just fetch-reference. Grade evidence_source by the cited study type: rodent, baboon and lamb evidence is MODEL_ORGANISM.
5. Preterm-infant studies. These are HUMAN_CLINICAL; guideline or review statements may need quote_role: REVIEW_SYNTHESIS.
6. Causal wiring. Connect the phenotypes (hypoxemia, wheeze, pulmonary hypertension) to pathophysiology nodes with bare-name downstream targets.
7. Before the PR. Run just validate, just validate-terms, just count-verified-snippets, and just validate-disorders. Add a history/ record.

Gaps Not Covered by This Research

• Verified PMIDs and abstract quotes for essentially every claim.
• Frequencies for each phenotype.
• Quality-of-life data.
• Transcriptomic and proteomic datasets.
• Clinical trial NCT identifiers.
• A GeneReviews baseline. None is expected, since BPD is not Mendelian; confirm with just check-genereviews.

Sources - Thébaud et al. 2019, PMC6986462 - BPD: Pathogenesis and Pathophysiology - Evidence for the Management of BPD in Very Preterm Infants - Definitions review, Frontiers in Pediatrics 2023

Reference Validation

Checked with linkml-reference-validator 0.3.0rc3.

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

• PMID:16943402 (1 mention) - A randomized trial of deep-brain stimulation for Parkinson's disease.
• shared terms: disease

Weighed against this report's own most characteristic terms: bpd, verified, pulmonary, hypertension, disease, lung, preterm, ventilation, verify, respiratory, infant, growth, lead, neonatal, oxygen, definition, postnatal, support, surfactant, week.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0019091 (1 mention) - the report calls it "given in the template; verify"; MONDO calls it bronchopulmonary dysplasia

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0002098 (1 mention) - the report calls it "Dyspnea / respiratory distress"; HP calls it Respiratory distress
• HP:0002092 (1 mention) - the report calls it "Pulmonary hypertension"; HP calls it Pulmonary arterial hypertension, and lists "Pulmonary artery hypertension" among its other names
• GO:0055093 (1 mention) - the report calls it "Processes: response to hyperoxia"; GO calls it response to hyperoxia
• CL:0002063 (1 mention) - the report calls it "Cells: type II pneumocyte"; CL calls it pulmonary alveolar type 2 cell, and lists "type II pneumocyte" among its other names
• UBERON:0002048 (1 mention) - the report calls it "Primary: lung"; UBERON calls it lung**